iBreastExam™ (iBE) is a US FDA cleared and CE marked, hand-held, mobile connected, radiation-free device operable by non-clinical resources for early detection of breast lumps at the PoC. Using a proprietary, non-invasive tactile sensor technology, iBE provides a painless and objective breast exam quickly in almost any physical setting. Data collected offline is mapped to a cloud-based web dashboard that provides real-time, location-wise data, and patient and population-level analytics. With 500+ units and 1M+ scans sold, iBE has benefitted 300K+ women with 150+ cancers diagnosed in 10 countries. iBE is being implemented in several large scale, population-based screening programs globally.

iBE is clinically validated in over 7,500 women with publications in journals like ASCO, SABCS, ASBS, WJSO. The Clinical Advisory Board is comprised of Global KOLs and experts in breast cancer care. iBE has been recognized by the W.H.O. in the latest compendium of Innovation Health Technologies. 

iBE has been deployed by the State Government of Maharashtra (India) to screen 250K+ women across 16 medical colleges in the State. So far, this program has reached more than 100K+ women with 120+ cancers diagnosed and treated, resulting in better clinical and social outcomes for women in this State.

• An ultra-portable, mobile connected device solution operable by non-clinical professionals.
• iBE creates equitable access for ALL women for early detection of breast cancer at the point of care.
• Unlike existing modalities, iBE has the potential to triage effectively at a population level to downstage breast cancer disease burden in LMICs.